Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza vaccine (split virion), inactivated (MDCK cell)
- Development stage
- Phase 3
- Lead developer
- Olymvax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **quadrivalent influenza vaccine (split virion), inactivated (MDCK cell)** is a cell-culture-derived vaccine designed to prevent seasonal influenza. Unlike traditional influenza vaccines produced in embryonated chicken eggs, this formulation utilizes **Madin-Darby Canine Kidney (MDCK)** cells for viral propagation. This method reduces the risk of egg-adaptive mutations that can decrease vaccine effectiveness and provides a safe alternative for individuals with egg allergies. The vaccine is quadrivalent, meaning it contains inactivated split virions from four different influenza virus strains: two influenza A subtypes (typically H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). It is currently being evaluated in clinical trials for safety and immunogenicity in populations aged 6 months and older.
- Other names
- 四价流感病毒裂解疫苗（MDCK细胞）quadrivalent cell-culture inactivated influenza vaccineccIIV4ccIIV-4ccIIV 4
02
Targets
Influenza hemagglutinin-specific B-cell receptorγδ TCR (T-cell receptor)TCR (T-cell receptor specific for influenza virus peptides)HA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent influenza vaccine (split virion), inactivated (MDCK cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza vaccine (split virion), inactivated (MDCK cell).